Literature DB >> 21720199

Therapeutic monoclonal antibodies.

Taketo Yamada1.   

Abstract

Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs). In the 35 years since the first process for creating MoAbs was introduced, they have remained the centerpiece of the growing biotechnology and pharmaceutical industry. Herein, I review the history, development, and clinical settings of therapeutic MoAbs that have had a significant impact on life-saving medicine.

Mesh:

Substances:

Year:  2011        PMID: 21720199     DOI: 10.2302/kjm.60.37

Source DB:  PubMed          Journal:  Keio J Med        ISSN: 0022-9717


  12 in total

1.  A platform for characterizing therapeutic monoclonal antibody breakdown products by 2D chromatography and top-down mass spectrometry.

Authors:  Matthew T Mazur; Richard S Seipert; David Mahon; Qinwei Zhou; Tun Liu
Journal:  AAPS J       Date:  2012-05-12       Impact factor: 4.009

Review 2.  Therapeutic monoclonal antibodies and clinical laboratory tests: When, why, and what is expected?

Authors:  Zhanhu Zhang; Wenjie Hu; Linlin Li; Hongxia Ding; Haibo Li
Journal:  J Clin Lab Anal       Date:  2017-08-15       Impact factor: 2.352

Review 3.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

Review 4.  Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17.

Authors:  N Landolina; F Levi-Schaffer
Journal:  Br J Pharmacol       Date:  2016-02-01       Impact factor: 8.739

5.  An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection.

Authors:  Mark Zanin; Zhen-Yong Keck; G Jonah Rainey; Chia-Ying Kao Lam; Adrianus C M Boon; Adam Rubrum; Daniel Darnell; Sook-San Wong; Yolanda Griffin; Jinming Xia; Robert G Webster; Richard Webby; Syd Johnson; Steven Foung
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

Review 6.  Anti-bacterial monoclonal antibodies: next generation therapy against superbugs.

Authors:  Hui Wang; Daijie Chen; Huili Lu
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-01       Impact factor: 4.813

7.  Expanded clinical and experimental use of SOX11 - using a monoclonal antibody.

Authors:  Lena Nordström; Ulrika Andréasson; Mats Jerkeman; Michael Dictor; Carl Borrebaeck; Sara Ek
Journal:  BMC Cancer       Date:  2012-06-27       Impact factor: 4.430

Review 8.  Targeted drug delivery for cancer therapy: the other side of antibodies.

Authors:  Michael A Firer; Gary Gellerman
Journal:  J Hematol Oncol       Date:  2012-11-09       Impact factor: 17.388

9.  Site-Specific Modification of Single-Chain Affinity Ligands for Fluorescence Labeling, Radiolabeling, and Bioconjugation.

Authors:  Boya Zhang; Sachith M Vidanapathirana; Colin F Greineder
Journal:  Methods Mol Biol       Date:  2021

Review 10.  Antidotes, antibody-mediated immunity and the future of pharmaceutical product development.

Authors:  Salvador Eugenio C Caoili
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.